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A REVIEW OF MULTIPLE
SCLEROSIS TREATMENTS:
INTERFERON BETA,
GLATIRAMER ACETATE,
FINGOLIMOD, AND
NATALIZUMAB
Written by Ryan Golden

Abstract
Multiple Sclerosis (MS) is an autoimmune disease in which the body’s own immune
system works to demyelinate the myelin sheaths in the central nervous system. The
beginning of the review will concentrate on the history of MS while also describing how
MS, the disease, differs from that of normal immune responses. The review then shifts to
the four different stages of MS and how to differentiate between the stages, since the
treatment options are often dependent on the stage of MS that the patient is in. The
main focus of this review is to take an in depth look on four specific medications for
treating MS: Interferon Beta, Glatiramer Acetate, Fingolimod, and Natalizumab. Each
medication will be described along with detailing their mechanism of action, or proposed
mechanism of action, and the specific stages of MS that it has been proven to help. While
there is no cure for MS, these medications have been implemented to help reduce the
flare-up (relapses) of the symptoms produced by this autoimmune disease. The
conclusions of the review offer some insight into newer research and possible paths that
researchers should consider.

Table of Contents
INTRODUCTION: ...................................................................................... 3
History of Multiple Sclerosis .................................................................................................................... 3
Disease Pathology ................................................................................................................................... 3

STAGES OF MULTIPLE SCLEROSIS: ........................................................... 4
Clinically Isolated Syndrome .................................................................................................................... 4
Relapse-Remitting Multiple Sclerosis ....................................................................................................... 5
Primary-Progressive Multiple Sclerosis .................................................................................................... 5
Secondary-Progressive Multiple Sclerosis ................................................................................................ 5

Treatments of Multiple Sclerosis ............................................................. 6
Interferon Beta ........................................................................................................................................ 6
What is Interferon beta? ...................................................................................................................... 6
Mechanism of Action of Interferon Beta ............................................................................................... 6
Stages that Interferon Beta Benefits .................................................................................................... 7
Glatiramer Acetate .................................................................................................................................. 8
What is Glatiramer Acetate? ................................................................................................................ 8
How does Glatiramer Acetate work? .................................................................................................... 8
Stages of Multiple Sclerosis that Glatiramer Acetate Benefits............................................................... 9
Fingolimod ............................................................................................................................................ 10
What is Fingolimod? .......................................................................................................................... 10
Mechanism of Action of Oral Fingolimod............................................................................................ 10
Stages of Multiple Sclerosis Oral Fingolimod has Provided Benefits .................................................... 11
Natalizumab .......................................................................................................................................... 11
What is Natalizumab?........................................................................................................................ 11
How does Natalizumab Work? ........................................................................................................... 12
Stages of Multiple Sclerosis that benefit from Natalizumab ................................................................ 13

Conclusions ........................................................................................... 13
Future Research .................................................................................................................................... 13
Acknowledgements ............................................................................................................................... 14

References ............................................................................................ 14
Appendix A ............................................................................................ 16
Appendix B ............................................................................................ 16

2

INTRODUCTION:
Multiple Sclerosis (MS) is an autoimmune
disease that effects the immune system. It
can often be characterized as a process that
causes demyelination of the central nervous
system (1). The continual degradation of
the myelin, which is important in the
signaling pathways in the nervous system,
can lead to disability. The interactions with
the specific T-cells and the blood-brain
barrier are of importance as well. While
there continues to be advances in
treatment to decrease the frequency of
episodes of MS, there is still no cure for the
disease (2). The pathological changes are
initiated by extensive microglial activation
which can lead to inflammatory lesions of
the central nervous system (2).

to provide promise for continued
exploration into treatments specific to MS.
DISEASE PATHOLOGY
How multiple sclerosis effects normal cells
can be a starting point to help find possible
treatments. Figure 1 shows the differences
in immune functions between a normal cell
and a MS cell.

Because of the complexity of MS,
and the fact that it effects each patient
differently, the focus of research and
treatments is to stop progression of
disease, restore lost function, and
ultimately to end MS for every patient (3).
HISTORY OF MULTIPLE SCLEROSIS
In 1946, there was little to be known on
multiple sclerosis, but this was the year in
which the National Multiple Sclerosis society
was founded. The following year, the
National MS society sponsored their first
three research projects. However, it wasn’t
until 1993 that the first treatment directly
for MS was approved and 2010 the first oral
treatment is brought to market (3). Funding
continues for extended trials that continue

Figure 1 Normal vs. MS compromised cell: In panel
A represents a normal suppression of myelinreactive T cells, while panel B represents how
myelin-reactive T cells become activated in multiple
sclerosis (4).

Panel “A” depicts an immune cell’s
normal reaction (4). The co-stimulatory
molecules along with CTLA-4 are shown to
regulate or suppress myelin-reactive T cells.
“B” gives a representation of how the
peripheral immune regulation is damaged
(4). Some main differences to note are the

increase in co-stimulatory molecules and
decrease in CTLA-4. These changes lead to
the activation of myelin-reactive T cells that
can cross the blood-brain barrier and
initiate an inflammatory response (4).

STAGES OF MULTIPLE
SCLEROSIS:
Multiple Sclerosis is a disease that can be
characterized by an impaired nervous
system. However, it can better be broken
down into four main stages: 1) Clinically
Isolated Syndrome 2) Relapse-Remitting 3)
Primary Progressive and 4) Secondary
Progressive (2).
Clinical signs can often provide
grounds to make a diagnosis of MS,
magnetic resonance imaging (MRI), is an
important method to support these findings
(5). There is a set of criteria that must be
met in order to provide the clinical
diagnosis of multiple sclerosis. This is
referred to as the “McDonald Criteria” by
the International Panel on Diagnosis of MS
(5). The McDonald Criteria was originally
written in 2001, but with the latest
revisions coming in 2013 (5). The McDonald
Criteria contains the guidelines as to the
different stages of MS and how to classify
the patient’s stage based on the presenting
conditions. It is important for the panel to
continually look at revisions as the
technology and research in MS advances.

CLINICALLY ISOLATED SYNDROME
Clinically isolated syndrome often refers to
the first step in multiple sclerosis. This stage
is a change in 2013 from the previous
stages listed in McDonald’s Criteria (6). It is
known to be an acute onset of
demyelination located in the central
nervous system (7). This syndrome is found
in approximately 90 percent of initial
presentations of MS and has become a key
diagnosis tool for early detection of MS (7).
There continues to be more
research on the importance of early
diagnosis and how it correlates to the
clinical course of MS. As a result, a recent
study by Kavaliunas, A. et. al in 2017,
worked to see the correlation of early
treatment initiation and time line of
disability.
The study included 639 patients that
were diagnosed with MS from 2001 to
2007. The study followed up with patients
in 99 months as the median amount of time
(8). The aim of the study was to find the
relationship of time of treatment to an
irreversible score of 4 on the Expanded
Disability Status Scale (EDSS).
EDSS is a score 0-10 that is given as a
determinant of the progression or stage
that is the MS is inhibiting on the patient’s
body. On this scale, a 0 would indicate that
the neurological exam is normal whereas a
10 would indicate death due to MS (9).
Signs of disability begin to show up at a
EDSS score of 2. The before mentioned
study from 2017 found that patients who
4

started their treatment later had a greater
risk of reaching EDSS 4, which was found to
increase by 7.4 percent for every year in
which they delayed the initiation of
treatment (8). It was concluded that early
treatment initiation had a positive
correlation (p < 0.001) with a better clinical
outcome (8).
The before mentioned study is just
one reason as to the importance of having
the diagnostic ability to discover MS in the
early stages. This can then give specialists
the opportunity to monitor someone who
may be at risk for developing multiple
sclerosis.
RELAPSE-REMITTING MULTIPLE
SCLEROSIS
Relapse-Remitting Multiple Sclerosis is
defined as an occurrence, recurrence, or
possible worsening of neurological
dysfunction that lasts more than 24 hours
(10). Of these dysfunctions, they must
become stabilized or resolved either
partially or completely after that time (10).
Relapse-Remitting Multiple Sclerosis
(RRMS) can be defined as having clearly
defined disease relapses that follow with
either a full recovery or with partial
recovery (11). It is between these relapses
that there is a period that lacks progression
of the disease, i.e. remitting (11).
This stage carries some defining
elements to RRMS. The episode of relapse is
dependent on the worsening of
neurological function but must also have

stability between attacks. A dissociation has
not been found within the disease between
patients that fully recover and those that
only partially recover (11).
PRIMARY-PROGRESSIVE MULTIPLE
SCLEROSIS
Primary-Progressive Multiple Sclerosis
(PPMS) is defined as the disease
progression from the onset of initial MS
with occasional plateaus and also having
temporary improvements that are minor
(11). The essential point to this stage of MS
is that it is characterized by an almost
continuous, but gradual worsening baseline
conditions of MS with minor improvements
to conditions, but no distinct relapses (11).
While RRMS does not have a
continual increase in disability, PPMS has
the increase in disability as time increases.
The plateaus of minor improvement may or
may not be seen in the patient, however it
is more likely than not that plateaus will be
seen (11).
SECONDARY-PROGRESSIVE MULTIPLE
SCLEROSIS
Secondary-Progressive Multiple Sclerosis
(SPMS) can be defined as RRMS as the
initial course of disease, but is followed by
progression that may or may not have
relapses, minor remissions, or plateaus (11).
It can be thought about that SPMS is the
longitudinal outcome of some, but not all
RRMS.
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The distinguishing characteristic from RRMS
and SPMS is the worsening of baseline
conditions from one stage to the other (11).
All four of the above stages can be
diagnosed by clinical symptoms, but a MRI
can give more accurate baseline
information. The purpose of the MRI is to
find evidence of brain and spinal lesion.
Lesions can be seen due to the contrast that
is injected. MRI was first used as a
diagnostic tool in 1981 (3).

TREATMENTS OF MULTIPLE
SCLEROSIS
In, 1993 the list of licensed multiple
sclerosis treatments was zero, but as of
March, 2017, 15 approved treatments exist.
As stated earlier, there are no known cures
for MS, but rather treatments that can
provide temporary improvements or
decrease in symptoms.
The aim for most treatments is to
help with symptoms to improve the quality
of everyday life. The following is a subset of
the growing list of disease-modifying
treatments for multiple sclerosis.
INTERFERON BETA
WHAT IS INTERFERON BETA?
Interferon beta is polypeptide that is
produced by fibroblasts in the body. This
polypeptide has anti-inflammatory effects
because of its inhibition of T-lymphocyte
proliferation (12). Only recombinant forms

of interferon beta are given for MS
treatment, interferon beta-1a and
interferon beta-1b. Interferon beta-1a is
given in doses of either 30 micrograms
intramuscularly once a week or
subcutaneously with doses of either 22 or
44 micrograms, while interferon beta-1b is
administered at a dose of 250 micrograms
subcutaneously every other day (12).
MECHANISM OF ACTION OF INTERFERON
BETA
Interferon beta has several proposed
potential mechanisms of action in regard to
multiple sclerosis. The precise mechanism
by which interferon beta produces its antiinflammatory and immunomodulatory
effects is still unclear (13). Those proposed
methods include inhibition of T-cell
activation and proliferation and also the
blood-brain barrier effects (13).
In an earlier section, the importance
of the decreased activation of myelinreactive T-cells was discussed (4). It has
been proposed that interferon beta
achieves that. This drug promotes an
increased expression of CTLA4, an
important regulator for T-cells (13). It was
also suggested in another study that
interferon beta leads to an increase in Fas
and CTLA4 induces apoptosis of such
autoreactive T cells (14). It can then be
suggested that the effects of interferon
beta lower the chances that pathogenic Tcells will become activated which leads the
processes of the events that is initiated in
MS cells.
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Another proposed mechanism is interferon
beta the decreases expression of molecules
needed for antigen presentation. Figure 2
shows that proposed mechanism.

Figure 3. Reaction to Interferon Beta Levels. The
above figure illustrates how an increase or a possible
decrease in interferon beta can halt T-cell adhesion
with the vascular endothelial basement membrane
and extravasation by central nervous system (14).

STAGES THAT INTERFERON BETA BENEFITS

Figure 2. Interferon-Beta Cascade. The above figure
displays interferon beta activation leads to
decreased generation of antigen-specific T cells (15).

A final proposed model of interferon
beta mechanisms of action are the effects
on the blood-brain barrier. Interferon beta
increases the serum concentrations of
soluble vascular cell adhesion molecule – 1
(sVCAM) (13). Figure 3 shows the proposed
model of interferon beta blood-brain
barrier effects.

Both types of interferon beta have been
found to work in multiple stages of multiple
sclerosis. For instance, in a study done in
2006, it was proposed that interferon beta1b given at 250 micrograms subcutaneously
every other day could be used as a
treatment option to delay patient’s
progression to RRMS from clinically isolated
syndrome (16).
The majority of the treatment was
for RRMS in reducing the annualized relapse
rate. Interferon beta was found to have
approximately 30%-34% reduction of
disability progression as well as decreased
disease activity seen on MRI (12).
Interferon beta has not been found
to be effective for PPMS, because they are
not designed for the pathogenic
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mechanisms that are employed in PPMS
(17). Whereas patients with SPMS have
found some benefit, but for patients to
experience this effect they must be
experiencing superimposed relapses (12).
GLATIRAMER ACETATE
WHAT IS GLATIRAMER ACETATE?
Glatiramer acetate is a group of synthetic
peptides that resembles sequences of
myelin basic protein, that often have
lengths from 40-100 residues (12). It is
thought to have its anti-inflammatory
effects based on its role with Th2 and antiinflammatory cytokines (12). Glatiramer
acetate can be given subcutaneously in 20
mg daily or by 40 mg three times weekly
(18).

HOW DOES GLATIRAMER ACETATE WORK?
The exact mechanism of glatiramer acetate
is, again, not completely known. There are
several proposed mechanisms that do exist
today.
The first is thought to deal with the
activation of glatiramer acetate Th2 specific
cells and the competition that occurs with
MHC molecules on the antigen-presenting
cells leads to suppression of the activation
of myelin-reactive Th1 cells (19). Figure 4
below, shows such proposed mechanism.

According to a study completed in 2015,
the higher, but less frequent dose of
glatiramer acetate had the following
effects:
•
•

•
•

Reduction of annualized relapse rate
in comparison to a placebo group
Suggest similar efficacy to that of
the lower, more frequent dosage of
glatiramer acetate
50 percent reduction of incidence of
side effects at injection site
Possibility to show an increase in
convenience with MS patients (18)

Due to this, recently there has been a
switch in dosing from the daily 20 mg to the
40 mg three times weekly.

Figure 4. Glatiramer Acetate Proposed Cascade.
The above figure demonstrates how the
presentation of glatiramer acetate as an antigen and
leads to generation of glatiramer acetate specific
Th2 cells is accomplished by either the high affinity
of glatiramer acetate for the MHC or by an uptake of
glatiramer acetate by an antigen presenting cell (15).

8

Another often suggested mechanism of
action involves the blood-brain barrier.
Figure 5 below shows this relationship. The
actions can be best seen by contrasting the
mechanism of interferon beta. (Gd means
gadolinium, the element)

activity (15). Gd enhancing MRI activity
contains a correlation to infiltration of
lymphocytes and also an increase in MMP
levels is observed to lead to the disruptions
of the blood-brain barrier (15)
Other proposed mechanisms that
are less understood include, glatiramer
acetate lowering the production of
cytokines by Th1 and imposing a
neuroprotective effect by neurotrophic
factors in the central nervous system (19).
STAGES OF MULTIPLE SCLEROSIS THAT
GLATIRAMER ACETATE BENEFITS
Glatiramer acetate at a subcutaneous
dosage of 20 mg daily has been found to be
effective, p=0.0005, for patients with
clinically isolated syndrome when
compared to a placebo trial of a 3 year time
period involving 481 patients (20).

Figure 5. Effects on BBB. The above figure shows the
effects that interferon beta and glatiramer acetate
have on the blood-brain barrier and eventually the
brain (15).

As seen in Figure 5, glatiramer acetate Th2
cells cross the blood-brain barrier to affect
the central nervous system function by a
possible bystander suppression of the
active myelin-reactive T cells. It also leads
to no decrease in T cell migration and a
delayed decrease of Gd-enhancing MRI

Glatiramer acetate has been most
effective in RRMS with the 20 mg daily dose
having a mean reduction of annualized
relapse rate of 29% (12). The glatiramer
acetate that is given at 40 mg three times
weekly was found to have a mean
annualized relapse rate of 34% (p<0.0001)
(18).
While glatiramer acetate has a high
reduction of annualized relapse rate for
clinically isolated syndrome and RRMS, it
has not been investigated in SPMS and has
shown no benefits for patients with PPMS
(21).
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FINGOLIMOD
WHAT IS FINGOLIMOD?
Fingolimod is the first oral form of a
disease-modifying therapy that is approved
for MS (22). It can be classified as a
sphingosine 1-phosphate (S1P) receptor
modulator (12). S1P is a natural lipid, in the
lysophospholipids family; these lipids act as
regulators for the pathogenesis of MS (22).

MECHANISM OF ACTION OF ORAL
FINGOLIMOD
Fingolimod is effective because it can cross
the blood-brain barrier and directly affect
the central nervous system (23). It has the
capabilities to induce adherent junction
assembly that can reduce the vascular
leakage that is experienced in the
pathogenesis of MS (22).
Fingolimod works to inhibit the
movement of the autoreactive lymphocytes
from the lymph nodes and penetrate the
central nervous system (12). Figure 7
represents these such actions.

Figure 6. Cells With S1P receptor. The above figure
depicts a summary of the different cells that have
the S1P receptor and are therefore affected by
fingolimod (22).

Past studies suggest that the S1P
receptors that are found in figure 6 have
been impaired in multiple sclerosis (22).
Fingolimod is usually given in oral
capsules at a dose of 0.5 mg or 1.25 mg
daily (12).

Figure 7. Mechanism of Action of Fingolimod. The
above figure represents how fingolimod works to
down-regulate S1P receptors located on the
lymphocytes in order to prevent the lymphocyte
movement from the lymphoid tissues to lead to
reduced penetration of destructive cells into the
central nervous system (23).
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NATALIZUMAB
WHAT IS NATALIZUMAB?
Natalizumab is a second line therapy that
has been found to have an astoundingly
high ARR at 68% (P<0.001) (12).
Natalizumab is a defined as a monoclonal
antibody that specifically blocks the
interaction of the ligands at the a4-integrin
which is a glycoprotein (25).

Figure 8. Effects of Fingolimod. The figure above
displays the effects that fingolimod treatment can
employ on different cells within the central nervous
system (22).

STAGES OF MULTIPLE SCLEROSIS ORAL
FINGOLIMOD HAS PROVIDED BENEFITS
Fingolimod has proven to have therapeutic
efficacy in patients with relapsing or
relapsing-remitting MS (23). For RRMS that
0.5 mg of fingolimod daily had a reduction
of annualized relapse rate by 48-55 percent
while also slowing disability by 25-30
percent in a study of 1272 patients
(p<0.001) (24).
There continues to be ongoing
investigations into the effectiveness of
fingolimod for PPMS and SPMS, but
additional trials are needed (22).

Another interesting difference in
natalizumab was the dosing instructions. In
contrast to the earlier discussed
treatments, natalizumab is a 300 mg,
intravenous infusion that is given every four
weeks (12).
In addition to the reduced
annualized relapse rate, a two-year, phase
III trial considered to be pivotal to
understanding natalizumab, also
demonstrated that it lowered the rate of
disability by 54% while also reducing
gadolinium-enhancing lesions seen on MRI
by 92% (p<0.001). The study consisted of
942 patients with 315 of those receiving
placebo infusions as a control (26).
However, with the high reductions
mentioned earlier, there is an increased risk
of developing a disease called progressive
multifocal leukoencephalopathy (PML) with
increased treatment time of natalizumab
(27). In other words, the longer the period a
patient receives natalizumab, there is an
increase in the risk of the patient
developing PML. PML is an infection from
John Cunningham virus (JCV) attacking the
oligodendrocytes of the CNS (12).
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Due to the severity of PML, it has
been imperative for MS patients to be
screened in order to identify those patients
who have been exposed to JCV because it is
possible that viral reactivation can occur on
immunosuppressed patients such as those
with MS. STRATIFY JC virusä, which is an
assay that measures anti-JC virus antibodies
that are present in the blood to identify
exposure to the JCV. Early results from the
study showed that anti-JC virus antibodies
were present in 54% of MS patients that
were treated with natalizumab (27).
Therefore, only patients that are JCVnegative use natalizumab for more than
two years and are tested every six months
to see if their JCV status changes (12).

endothelial cells are known to express. This
interaction leads to a reduction of leukocyte
integration in the CNS which in turn lowers
the activity of MS (30). This interaction is
depicted in figure 9 below.

HOW DOES NATALIZUMAB WORK?
As stated before, natalizumab is
monoclonal antibody that functions to
block the a4-integrin, more specifically the
a4b1-integrin (VLA-4) from binding. It’s
believed mechanism of action is inhibition
of autoreactive T cells entering into the
CNS. In the same study, it was also thought
that natalizumab could also be affected by
pathogenic B cells in a similar way (28). This
proves to be promising due to the fact that
natalizumab binding to VLA-4 had a 49%
reduction for B cells versus only 24.5%
reduction of T cells. This was also
accompanied by an increase in circulating B
cells over T cells (29).
The main concern of understanding how
natalizumab works in RRMS is the
interactions between the VLA-4, which is
seen in mononuclear inflammatory cells,
and vascular cell adhesion molecule-1
(VCAM-1) expressed by cerebral vascular

Figure 9. Natalizumab effects on MS. The a4b1integrin binds to the VCAM-1, which then allows the
autoreactive T cell to enter the CNS. Natalizumab
does not allow the a4b1-integrin and VCAM-1 to
bind and allow the T cell to penetrate the bloodbrain barrier to damage the myelin sheath (31).

Another possible mechanism in which
natalizumab helps with MS is Osteopontin
levels in plasma, which are elevated in
comparison to a healthy patient and even
more so in CSF (30). In a 2 year study of 49
patients with RRMS, it was shown that
natalizumab reduced Osteopontin levels by
31% (P<0.005). Also, it showed
improvement in patients’ cognitive
impairment (P<0.005) (32). It can be
suggested from this data that increased
Osteopontin levels can lead to cognitive
impairment.
As this treatment continues to become
increasingly implemented, it continues to
have possible mechanisms of action that
12

attempt to explain how it works. The main
point being the interaction that occurs
between the VLA-4 and VCAM-1.
STAGES OF MULTIPLE SCLEROSIS THAT
BENEFIT FROM NATALIZUMAB
Natalizumab has the majority of its
documented literature on how the
treatment helps with RRMS, the 68%
reduction in ARR stated earlier. As of March
2017, natalizumab is only documented to
be effective against RRMS.
In 2011, there was a phase IIIb study on
natalizumab in SPMS called ASCEND (30).
However, in June of 2017 this trial was
terminated for not having statistically
significant findings. While this can be
discouraging to researchers, there is still
hope for finding a clinical benefit to
understanding how the BBB is disturbed in
progressive forms of MS.

CONCLUSIONS
Treatment for multiple sclerosis has come a
long way in the last 24 years since the first
drug treatments began to be produced.
There looks to be continual upside to
treatments of multiple sclerosis as ongoing
trials are completed. Fingolimod continues
to be an increasingly popular drug for the
MS community because of the convenience
of the oral version and the possibility of
helping with non-relapsing forms of MS.
While the focus of this review was on four
specific treatments for the neurological
disease pathway, it should also be noted
that there are multiple different

medications that MS patients use in order
to treat other symptoms that are
accompanied by this disease.
For example, onabotulinum toxin type A
(Botox), which is normally for the treatment
of muscle stiffness, in 2011 was approved
to treat urinary incontinence in MS
patients. Botox is also used to help to
control with spasticity (increase in tonic
stretch reflexes) with injection directly into
the skeletal muscle (33).
FUTURE RESEARCH
As stated above, future research needs to
be done in order to continue to help people
that are affected by this widely seen
autoimmune disease. The increases in
technology should continue to be a benefit
to researchers in hopes to continue to
enhance current medication, but also the
possibility of development of new targeted
treatments for MS (27).
The most important research could come
from an increase in studies to help clarify
mechanism of action of these four drugs
discussed in this review. Many of the
mechanisms continue to remain unknown,
which could impede research efforts.
Knowing the possible mechanism could
provide the opportunity to allow physicians
to better select appropriate drugs for
treatment (13, 30, 34).
Another possibility in future research could
focus on the ability of the drug to influence
not only the immune system but also
pathological changes that occur in MS. The
13

more that can be learned about the actual
pathology, the better and more precise the
treatments can be.
Long term effects of the disease modifying
treatments should also continue to be
studied. Not only for the patient, but the
physician so that they can estimate when a
medication change should be made.
A newer approach that is just starting to be
explored is the effects that melatonin has
on the immune response in MS. A study
done in 2017 was the first to demonstrate
that melatonin can reduce Th1 and Th22
pathogenic responses in MS patients. The
results also suggested that melatonin
increases the ratio of anti-inflammatory vs.
pro-inflammatory peripheral cells (35). This
could provide yet another possible avenue
for advancement in research.
Throughout this review, the current forms
of treatments have shown efficacy for
RRMS, future research should also look into
options for treatment for PPMS and SPMS.
The main area of continued research should
focus on the mechanisms of action of
current treatments.
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APPENDIX A
Citations for “A Review of Multiple Sclerosis
Treatments: Interferon Beta, Glatiramer
Acetate, Fingolimod, and Natalizumab”
were cited in NLM format.

APPENDIX B
The external reviewer for this review was
Dr. Jerome Freeman a Neurologist at
Sanford Neurology Clinic in Sioux Falls, SD.
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He has been a tremendous help in his
review of the first draft of this review.
The following is his remarks on the first
draft of this review:
“I reviewed your manuscript “Review of
Multiple Sclerosis and Treatment
Options”. You have a lot of good
information in the paper. I want to point
out a couple of things. It is not known for
sure how interferon beta and glatiramer
acetate work. You provide some good
explanations. Generally it is thought that
interferon tends to work more peripherally
and glatiramer more in the central nervous
system itself. Both seem to reduce the
annualized relapse rate (ARR) by about
30%. There are multiple other, newer
therapies available now. You mention
Fingolimod. It is estimated that Fingolimod
causes an ARR reduction of about 54 to
60%. Another oral agent is
Teriflunomide. That causes an ARR
reduction of about 31% and it’s not used as
much as the other oral agents. A third oral
agent is Dimethyl Fumarate. This causes an
ARR reduction rate of about 53%. Currently
one of the most aggressive MS therapies
available is Natalizumab. This is a once a
month IV injection. It reduces the ARR by
about 68%. It is associated with a
dangerous viral condition (progressive
multifocal leukoencephalopathy
(PML)). This only tends to occur in people
who carry the James Cunningham virus,
which is about 50% of the
population. Generally this drug is used in
people who are JC virus negative. Other

options include Alemtuzumab (monoclonal
antibody). A new drug that appears to be
very effective is Ocrelizumab. This also is a
humanized monoclonal antibody. Basically
people get an infusion of this every 6
months. Thus you can see that there are
considerably more options than the three
therapies you mentioned.”
After Dr. Freeman’s comments, I decided to
narrow the title down to the four
treatments reviewed as to be more specific.
I chose to add Natalizumab because the
PML component was interesting.
Continuing with Dr. Freeman’s comments:
“I’ll make some other brief comments
about the manuscript. In your introduction
you note MS as a “failure of the central
nervous system to perform
remyelination”. Actually I would
characterize it foremost as a process that
causes demyelination. There is now
evidence that in addition to attacking
myelin, MS also has an adverse effect on
axons. On page three under your “stages of
multiple sclerosis” the second paragraph
starts with two phrases that aren’t
complete sentences. On page four, I think
most experts refer to “relapsing-remitting
multiple sclerosis” rather than using the
term “relapse”. The hallmark of this type of
MS is that people get an attack and then
recover (often 100%). Sometimes some
mild residual symptoms persist. I think
characterizing the “remission” is important
rather than just the “lacks progression” that
you mention. On page five under
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“secondary-progressive multiple sclerosis”
you imply in the first paragraph that all
people with RRMS proceed to a secondary
progressive phase. That is not necessarily
the case. I think it would be better to
indicate that SPMS is the outcome of some
patients with RRMS. On page six (second
paragraph) the first sentence is not
complete. Before reference #3 I think you
would want to say something like “was
mentioned”. Also in the next sentence you
say that interferon beta “does such that”. I
think it would be better to say “achieves
that”. On page seven at the bottom of the
first column you indicate “affective”. It
should be “effective”. Also in the second
column on page seven the third bullet point
mentions “50 percent reduction of
incidence at reaction site”. I’m not sure
what that pertains to.”
I took all of his grammatical and word
choice suggestions to better the review.
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